Study identifier:D9617C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy of esomeprazole 40 mg once daily versus placebo & esomeprazole 20 mg once daily versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs
GERD
Phase 3
No
Esomeprazole
All
808
Interventional
18 Years +
Allocation: Randomized 
Endpoint Classification: Efficacy Study 
Intervention Model: Parallel Assignment 
Masking: Double Blind 
Primary Purpose: Treatment 
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
| Arms | Assigned Interventions | 
|---|